Grufity logo
Grufity logo

Latest Fairmount Funds Management LLC Stock Portfolio

$1.38Billion– No. of Holdings #12

Fairmount Funds Management LLC Performance:
2026 Q1: 18.26%YTD: 18.26%2025: 70.58%
Performance for 2026 Q1 is 18.26%, and YTD is 18.26%, and 2025 is 70.58%.

About Fairmount Funds Management LLC and 13F Hedge Fund Stock Holdings

On 2026-05-15, the fund reported it's updated stock portfolio. In the 13F Holdings report, Fairmount Funds Management LLC reported an equity portfolio of $1.4 Billions as of 31 Mar, 2026.

The top stock holdings of Fairmount Funds Management LLC are GLTO, , COGT. The fund has invested 16.3% of it's portfolio in DAMORA THERAPEUTICS INC and 15.4% of portfolio in DIANTHUS THERAPEUTICS INC.

The fund managers got completely rid off NUVALENT INC (NUVL) and KINIKSA PHARMACEUTICALS INTL stocks. They significantly reduced their stock positions in APOGEE THERAPEUTICS INC and COGENT BIOSCIENCES INC (COGT). Fairmount Funds Management LLC opened new stock positions in DAMORA THERAPEUTICS INC (GLTO). The fund showed a lot of confidence in some stocks as they added substantially to DIANTHUS THERAPEUTICS INC.
Fairmount Funds Management LLC Equity Portfolio Value
Last Reported on: 15 May, 2026

Fairmount Funds Management LLC Annual Return Estimates Vs S&P 500

Our best estimate is that Fairmount Funds Management LLC made a return of 18.26% in the last quarter. In trailing 12 months, it's portfolio return was 135.55%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
damora therapeutics inc225,667,000
New stocks bought by Fairmount Funds Management LLC

Additions

Ticker% Inc.
dianthus therapeutics inc18.72
zenas biopharma inc6.79
Additions to existing portfolio by Fairmount Funds Management LLC

Reductions

Ticker% Reduced
apogee therapeutics inc-85.42
enliven therapeutics inc-50.00
cogent biosciences inc-38.87
Fairmount Funds Management LLC reduced stake in above stock

Sold off

Ticker$ Sold
kiniksa pharmaceuticals intl-54,437,100
nuvalent inc-73,185,600
Fairmount Funds Management LLC got rid off the above stocks

Sector Distribution

Fairmount Funds Management LLC has about 57.4% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare57.4
Others42.6

Market Cap. Distribution

Fairmount Funds Management LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.

  • UNALLOCATED
  • MID-CAP
  • NANO-CAP
  • SMALL-CAP
Category%
UNALLOCATED42.6
MID-CAP35.5
NANO-CAP16.3
SMALL-CAP4.6

Stocks belong to which Index?

About 25.5% of the stocks held by Fairmount Funds Management LLC either belong to S&P 500 or RUSSELL 2000 index.

  • Others
  • RUSSELL 2000
Index%
Others74.5
RUSSELL 200025.5
Top 5 Winners (%)%
enliven therapeutics inc
115.9 %
dianthus therapeutics inc
88.3 %
oruka therapeutics inc
61.8 %
crescent biopharma inc.
54.9 %
AGLE
spyre therapeutics inc
54.0 %
Top 5 Winners ($)$
dianthus therapeutics inc
99.8 M
AGLE
spyre therapeutics inc
71.0 M
oruka therapeutics inc
69.4 M
enliven therapeutics inc
66.2 M
COGT
cogent biosciences inc
21.5 M
Top 5 Losers (%)%
zenas biopharma inc
-45.4 %
VRDN
viridian therapeutics inc
-37.1 %
IKT
inhibikase therapeutics inc
-18.1 %
AVTE
jade biosciences inc
-8.9 %
Top 5 Losers ($)$
VRDN
viridian therapeutics inc
-45.3 M
zenas biopharma inc
-38.3 M
AVTE
jade biosciences inc
-6.3 M
IKT
inhibikase therapeutics inc
-3.2 M

Fairmount Funds Management LLC Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Fairmount Funds Management LLC

Fairmount Funds Management LLC has 12 stocks in it's portfolio. VRDN proved to be the most loss making stock for the portfolio. was the most profitable stock for Fairmount Funds Management LLC last quarter.

Last Reported on: 15 May, 2026
TickerNamesorted ascending% PortfolioShares Held$ ValueType% ChangeOptions